A Relative Bioavailability Study of 100 mg Flavoxate Hydrochloride Tablets Under Fasting Conditions
Launched by PADAGIS LLC · Oct 8, 2009
Trial Information
Current as of May 22, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Good health as determined by lack of clinically significant abnormalities in health assessment performed at screening
- Exclusion Criteria:
- • Positive test results for HIV or Hepatitis B or C
- • History of allergy or sensitivity to Flavoxate hydrochloride or related drugs
About Padagis Llc
Padagis LLC is a dedicated pharmaceutical company focused on the development and commercialization of innovative therapeutic solutions that enhance patient outcomes. With a commitment to advancing healthcare, Padagis specializes in generic and specialty pharmaceuticals, leveraging cutting-edge technology and rigorous clinical research to deliver high-quality, affordable medications. The company prioritizes patient safety and efficacy in its clinical trials, aiming to address unmet medical needs across various therapeutic areas. Through strategic partnerships and a robust pipeline, Padagis is poised to make a significant impact in the pharmaceutical landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Fargo, North Dakota, United States
Patients applied
Trial Officials
Carlson, Pharm.D.
Principal Investigator
PRACS Institute, Ltd.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials